Toward a treatment for pachyonychia congenita: Report on the 7th annual international pachyonychia congenita consortium meeting

Journal of Investigative Dermatology

Volumn 131, Issue 5, 2011, Pages 1011-1014

  Kaspar, Roger L ^a,b   Leachman, Sancy A ^c   McLean, W H Irwin ^d   Schwartz, Mary E ^e  

^a TransDerm Inc   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e Pachyonychia Congenita Project   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NUCLEIC ACID; RETINOID; SMALL INTERFERING RNA;

ARTICLE; CONGENITAL PACHYONYCHIA; DATA BASE; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LIFE EVENT; MOLECULAR THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN;

CLINICAL TRIALS AS TOPIC; HUMANS; PACHYONYCHIA CONGENITA; RNA, SMALL INTERFERING;

EID: 79954599490     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.44     Document Type: Article

References (11)

1. Eliason MJ, Leachman SA, Feng BJ et al. A review of the clinical phenotype in 254 patients with genetically confirmed pachyonchia congenita. JAAD (unpublished)
2. Fu T, Leachman SA, Wilson NJ et al. (2011) Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. J Invest Dermatol 131:1025-8
3. García M, Larcher F, Hickerson RP et al. (2011) Development of skin-humanized mouse models of pachyonychia congenita. J Invest Dermatol 131:1053-60
4. Gruber R, Edlinger M, Kaspar RL et al. (2011) An appraisal of oral retinoids in the treatment of pachyonychia congenita. JAAD (In Press)
5. Hickerson RP, Leake D, Pho LN et al. (2009) Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonchia congenita patients. J Invest Dermatol 56: 82-88
6. Hickerson RP, Leachman SA, Pho LN et al. (2011a) Development of quantitative molecular clinical end points for siRNA clinical trials. J Invest Dermatol 131: 1029-36
7. Hickerson RP, Flores MA, Leake D et al. (2011b) Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. J Invest Dermatol 131:1037-1044
8. McLean WHI, Hansen D, Eliason M et al. (2011) The phenotypic and molecular genetic features of pachyonychia congenita. J Invest Dermatol 131:1015-7
9. Ra H, Piyawattanametha W, Gonzalez-Gonzalez E et al. (2011) In vivo imaging of human and mouse skin with a handheld dual-axis confocal fluorescence microscope. J Invest Dermatol 131:1061-6
10. Wilson NJ, Leachman SA, Hansen CD et al. (2011) A large mutational study in pachyonychia congenita. J Invest Dermatol 131: 1018-24
11. Zhao Y, Gartner U, Smith FJD et al. (2011) Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol 131:1045-52